Medtelligence

Host: Hongya Chen, PharmD Guest: Jennifer Day, PharmD Guest: Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA Join us in this educational endeavor to empower pharmacists with the latest insights and strategies for improved decision-making in ATTR-CM management. The program emphasizes the latest clinical insights in this evolving therapeutic landscape, addressing changes in diagnostic approaches over the last decade, and providing a nuanced perspective on ATTR-CM progression for more effective patient care. Don’t miss out on this opportunity to elevate the standard of care for your patients.

Host: Mikhail Kosiborod, MD Guest: Biff F. Palmer, MD Delve into refining the management of hyperkalemia in CKD patients and their associated comorbidities, striking a delicate balance that preserves guideline-recommended RAASi therapy. Join Dr. Biff Palmer and Dr. Mikhail Kosiborod as they guide the exploration of novel potassium binders for optimal hyperkalemia management, all while upholding the integrity of established treatment guidelines.

Host: Elana Koss, MD Guest: Hemal Gada, MD "The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Host: Ashish Aneja, MD "The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Host: Deepak Talreja, MD, FACC Host: Roxana Mehran, MD "The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Host: Anene Ukaigwe, MD "The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Host: Pam R. Taub, MD, FACC, FASPC Guest: Steven Yakubov, MD, MSCAI, FACC "The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Host: Hemal Gada, MD "The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Host: Renuka Jain, MD Guest: Steven Yakubov, MD, MSCAI, FACC "The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Host: Renuka Jain, MD "The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Host: William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE Guest: Georges Chahoud, MD, FACC, FAHA, FHFSA, FASE Guest: Patrick J. McCann, MD Even with guideline-directed medical therapy, or GDMT, many patients with heart failure are limited in their daily activities, due to increasing symptoms and reduced functionality. However, new data from BeAT-HF, a clinical trial that examines the long-term effects of baroreflex activation therapy, or BAT, shows that BAT may provide patients with sustained and durable benefits in exercise capacity, functional status, and quality of life.

Host: Raymond Townsend, MD Despite many available drug therapies, patients with hypertension continue to experience elevated blood pressures, putting them at risk for cardiovascular-related morbidities and mortality. However, renal denervation, a minimally invasive procedure, has been shown to result in sustained and durable reductions in blood pressure. Find out what this approach could mean for your patients.

Host: Martha Grogan, MD, FACP, FACC Guest: Marianna Fontana, MD Guest: Nitasha Sarswat, MD Once considered rare and untreatable, amyloid transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) has increased in incidence over the last decade and is now a treatable condition. This is partly due to our better understanding of the biology of the disease and recognition of its comorbid or co-occurring conditions in both cardiac and noncardiac patients with cardiac amyloidosis. In an open discussion, chairperson Martha Grogan, MD, and faculty members Marianna Fontana, MD, and Nitasha Sarswat, MD, provide an updated review of the disease state that includes a better understanding of the mechanism of the disease, discuss the pathogenic and protective genetic variants, and examine evidence from clinical trials that are impacting the evolving landscape.

Host: George L. Bakris, MD, FAHA, FASN Guest: David Bushinsky, MD Guest: Lars Lund, MD Hyperkalemia is a limiting factor when treating patients with heart failure and CKD on RAASi therapy. It’s especially challenging when these patients are on chronic hemodialysis. Join Drs. George Bakris, David Bushinsky, and Lars Lund as they identify the barriers of optimal treatment in patients on hemodialysis and discuss the real-world evidence using potassium-lowering agents in challenging patient group.

Host: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Guest: M. Luiza Caramori, MD, PhD, MSc Guest: Ana Maria Cebrián-Cuenca, MD, PhD Guest: Pam R. Taub, MD, FACC, FASPC Optimal treatment with guideline-directed therapies, including RAS inhibitors, SGLT2 inhibitors, and nonsteroidal MRAs, is paramount in preventing progressive renal dysfunction and cardiorenal events in patients with chronic kidney disease and type 2 diabetes. As the patient becomes more complex, a multidisciplinary approach is often necessary to improve their outcomes. Listen in as our panel of experts offers strategies to improve collaboration and patient care.

Host: Antoni Bayés-Genís, MD, PhD, FESC, FHFA Guest: Patrick Rossignol, MD, PhD Heart failure and chronic kidney disease can go hand in hand in your patients, and when they do, there are often added comorbidities such as diabetes. If your patients on RAASi therapy develop hyperkalemia, what should you do? Join Drs. Patrick Rossignol and Antoni Bayés-Genís as they consult on a patient with heart failure who has multiple comorbidities and discuss the impact of hyperkalemia in these complex patients.

Guest: Mazen Hanna, MD Guest: Marianna Fontana, MD Once thought to be a rare disease, transthyretin amyloidosis that results in cardiomyopathy (ATTR-CM) remains a challenge to diagnose and treat. In this discussion, Drs. Mazen Hanna and Marianna Fontana provide expert advice on imaging techniques to diagnose ATTR-CM, including recognizing diagnostic “red flags.” They also review recent clinical trial data of current and potential therapeutics for ATTR-CM, so listen in to find out how you can put the evidence into practice.

Host: Nirav Y. Raval, MD, FACC Guest: Gurusher Panjrath, MD, FACC, FAHA, FHFSA This program is no longer available for credit. Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Nirav Raval and Gurusher Panjrath explore data on its positive effects on exercise capacity, functional status, and quality of life. Do you know which of your patients may benefit from BAT?

Guest: Robert A. Baldor, MD Guest: Chadwick R. Johr, MD This innovative, 45-minute, case-based CME activity features two prominent faculty covering important, timely issues and data related to the detection of autoimmune (AI) disorders. Using case studies, the faculty will explore diagnosis and management strategies to maximize patient care. In addition to the analysis of AI cases, key topics will be covered, including:

Guest: Robert A. Baldor, MD Guest: Chadwick R. Johr, MD This innovative, 30-minute, online activity features a Video Expert Dialogue with two prominent faculty covering important, timely issues and data related to the detection of autoimmune (AI) disorders. The emphasis is on the unique role primary care providers play in diagnosing and managing AI and maximizing patient care. Topics include: We’ll be discussing autoantibody testing for autoimmune diseases, or more precisely, connective tissue diseases. Our purpose here is to discuss how autoantibody testing, such as the ANA, may be used in the primary care setting to diagnose these disorders. Using the ANA test combined with a good medical exam and a good history, along with signs and symptoms of connective tissue diseases, will help to achieve greater benefits in diagnosing and treating patients.